Pharscin Pharma obtained the drug registration certificate for Crizotinib capsules
I'm PortAI, I can summarize articles.
Pharscin Pharma has obtained the drug registration certificate for Crizotinib capsules issued by the National Medical Products Administration. This drug was launched in the Chinese market in 2013 and was included in the medical insurance system in 2018, with over ten years of clinical application experience, primarily used for the treatment of patients with advanced non-small cell lung cancer who are ALK-positive and ROS1-positive
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments